Athghin Biotechnology Inc is categorized under Commercial Biotechnical Research in Rensselaer, NY and active since 2012.
Athghin Biotechnology Inc was established in 2012, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact David Eveleth at the company’s single location by writing to 1 Discovery Drive, Rensselaer, New York NY 12144 or by phoning (518) 694-8188. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Athghin Biotechnology Inc |
| Contact Person: | David Eveleth |
| Address: | 1 Discovery Drive, Rensselaer, New York 12144 |
| Phone Number: | (518) 694-8188 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Athghin Biotechnology Inc was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact David Eveleth for inquiries that concern Athghin Biotechnology Inc by calling the company number (518) 694-8188, as your correspondence is most welcome. Additionally, the physical location of the single location of Athghin Biotechnology Inc can be found at the coordinates 42.626395,-73.739677 as well as the street address 1 Discovery Drive in Rensselaer, New York 12144.
For its online presence, you may visit Athghin Biotechnology Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.